Send to

Choose Destination
N Engl J Med. 2013 Aug 29;369(9):809-18. doi: 10.1056/NEJMoa1213917.

Macitentan and morbidity and mortality in pulmonary arterial hypertension.

Collaborators (181)

Lang I, Delcroix M, Nielsen-Kudsk JE, Ghofrani A, Wirtz H, Bruch L, Rosenkranz S, Klose H, Höffken G, Ewert R, Neurohr C, Behr J, Grünig E, Pfeifer M, Wilkens H, Vizza CD, Snijder RJ, Atar D, Broto A, Sánchez MA, Barberá JA, San Juan MV, Wikström G, Ekmehag B, Rådegran G, Coghlan G, Sitbon O, Dromer C, Bourdin A, Tomulic V, Varabei A, Pimanov S, Adzerikho I, Tzonzarova M, Forster T, Simor T, Temesvári A, Karlócai K, Torbicki A, Podolec P, Poloński L, Ginghina C, Bogdan MA, Barbarash OL, Chazova I, Evtushenko A, Lenskaya L, Arkhipov M, Chuchalin A, Ershova O, Shostak N, Moiseeva O, Rudakova T, Jovanović I, Putniković B, Mitić-Milikić M, Goncalvesová E, Šimková I, Dzyak G, Abrahamovych O, Küçükoglu S, Williams T, Keogh A, Youssef P, Nash P, Jing Z, Chen SL, Shen J, Zhou D, Zeng X, Zhang W, Wang G, Yao H, Wang H, Lee SW, Tam LS, Sharma K, Sathe S, Udwadia ZF, Sastry BK, Raghuraman B, Tyagi S, Kerkar PG, Chew D, Lim ST, Yip J, Hsu HH, Lan JL, Tanomsup S, Durongpisitkul K, Louthrenoo W, Nanagara R, Williams P, Essop MR, Sliwa-Hahnie K, Middlemost S, Abelson M, Doubell A, Adir Y, Kramer M, Ben-Dov I, Fink G, Man A, Bortman G, Cáneva JO, Chertcoff F, Diez F, Perna ER, Amuchástegui M, Gené RJ, Brasca D, Galvez PF, Sepulveda P, Zagolin M, Villamil JR, Luengas CA, Pulido-Zamudio TR, Días CJ, Camere M, Rodriguez AE, Hirani N, Granton J, Mehta S, Provencher S, Levy R, Badesch D, Rosenzweig E, Bourge R, Boyce P, Burger C, Cabuay B, Hansdottir S, de Boisblanc B, Elliott CG, Engel PJ, Farber HW, Hill N, Hsu V, McConnell JW, McLaughlin V, Michaelson J, Oudiz R, Kim HS, Williamson T, Bartolome SD, Chakinala M, Feldman J, Frost A, Gomberg-Maitland M, Park MH, Sager J, Sood N, Tapson V, Fortin T, Wirth J, Zwicke DL, Fisher M, Robbins I, Shapiro S, Chin K, Eggert M, Channick R, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Mehta S, Pulido T, Rubin LJ, Sastry BK, Simonneau G, Sitbon O, Souza R, Torbicki A, McGoon M, Peacock A, Nicod L, Eisen HJ, Nashan B, O'Connor C, DeMets DL.

Author information

Cardiopulmonary Department, Ignacio Chávez National Heart Institute, Mexico City, Mexico.



Current therapies for pulmonary arterial hypertension have been adopted on the basis of short-term trials with exercise capacity as the primary end point. We assessed the efficacy of macitentan, a new dual endothelin-receptor antagonist, using a primary end point of morbidity and mortality in a long-term trial.


We randomly assigned patients with symptomatic pulmonary arterial hypertension to receive placebo once daily, macitentan at a once-daily dose of 3 mg, or macitentan at a once-daily dose of 10 mg. Stable use of oral or inhaled therapy for pulmonary arterial hypertension, other than endothelin-receptor antagonists, was allowed at study entry. The primary end point was the time from the initiation of treatment to the first occurrence of a composite end point of death, atrial septostomy, lung transplantation, initiation of treatment with intravenous or subcutaneous prostanoids, or worsening of pulmonary arterial hypertension.


A total of 250 patients were randomly assigned to placebo, 250 to the 3-mg macitentan dose, and 242 to the 10-mg macitentan dose. The primary end point occurred in 46.4%, 38.0%, and 31.4% of the patients in these groups, respectively. The hazard ratio for the 3-mg macitentan dose as compared with placebo was 0.70 (97.5% confidence interval [CI], 0.52 to 0.96; P=0.01), and the hazard ratio for the 10-mg macitentan dose as compared with placebo was 0.55 (97.5% CI, 0.39 to 0.76; P<0.001). Worsening of pulmonary arterial hypertension was the most frequent primary end-point event. The effect of macitentan on this end point was observed regardless of whether the patient was receiving therapy for pulmonary arterial hypertension at baseline. Adverse events more frequently associated with macitentan than with placebo were headache, nasopharyngitis, and anemia.


Macitentan significantly reduced morbidity and mortality among patients with pulmonary arterial hypertension in this event-driven study. (Funded by Actelion Pharmaceuticals; SERAPHIN number, NCT00660179.).

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center